Microba has announced the completion of a Series A Investment Round three weeks early on the back of "strong demand".
The company has raised $7 million to support the launch of its gut microbiome profiling services, including the construction of a laboratory at Princess Alexandra Hospital in Brisbane.
Microba acquired the intellectual property for its first gut microbiome testing product, Microba Insight, from the University of Queensland in October 2017.
The test based on genome sequencing technologies provides detailed insights into a person's Gut Microbiome, helping them to gain an understanding of their personal microbiome through profiling of the bacteria, archaea, fungi, and protists in their gut at the species level.
The company's board of directors includes Ian Frazer AO, known for his leading role in the development of the HPV vaccine against cervical cancer.
Microba is moving towards its June 2018 launch date and has received over 1,000 pre-orders for its test since announcing the pre-launch campaign.